Predicting the oxidative metabolism of statins:: An application of the MetaSite® algorithm

被引:21
作者
Caron, Giulia
Ermondi, Giuseppe
Testa, Bernard
机构
[1] Dipartimento Sci & Tecnol Farm, I-10125 Turin, Italy
[2] CHU Vaudois, Univ Hosp, Dept Pharm, CH-1011 Lausanne, Switzerland
关键词
in silico; metabolism prediction; MetaSite; molecular fields; statins;
D O I
10.1007/s11095-006-9199-7
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Purpose: This study was undertaken to examine the MetaSite algorithm by comparing its predictions with experimentally characterized metabolites of statins produced by cytochromes P450 (CYPs). Methods: Seven statins were investigated, namely atorvastatin, cerivastatin, fluvastatin, pitavastatin and pravastatin which are (or were) used in their active hydroxy-acid form, and lovastatin and simvastatin which are used as the lactone prodrug. But given the fast lactone-hydroxy-acid equilibrium undergone by statins, both forms were investigated for each of the seven drugs. The MetaSite version 2.5.3 used here contains the homology 3D-models of CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4. In addition, we also used the crystallographic 3D-structure of human CYP2C9 and CYP3A4. To allow a better interpretation of results, the probability function P (SM) i calculated by MetaSite (namely the probability of atom i to be a site of metabolism) was explicitly decomposed into its two components, namely a recognition score Ei (the accessibility of atom i) and the chemical reactivity Ri of atom i toward oxidation reactions. Rewards: The current version of MetaSite is known to work best with prior experimental knowledge of the cytochrome(s) P450 involved. And indeed, experimentally confirmed sites of oxidation were correctly given a high priority by MetaSite. In particular 77% of correct predictions (including false positive but, as discussed, this is not necessarily a shortcoming) were obtained when considering the first five metabolites indicated by MetaSite. Conclusion: To the best of our knowledge, this is the first independent report on the software. It is expected to contribute to the development of improved versions, but above all it demonstrates that the usefulness of such softwares critically depends on human experts.
引用
收藏
页码:480 / 501
页数:22
相关论文
共 66 条
[1]
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors [J].
Afzelius, L ;
Zamora, I ;
Masimirembwa, CM ;
Karlén, A ;
Andersson, TB ;
Mecucci, S ;
Baroni, M ;
Cruciani, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (04) :907-914
[2]
The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[3]
[Anonymous], 2004, INT C SER, DOI DOI 10.1016/J.ICS.2003.12.099
[4]
Boberg M, 1997, DRUG METAB DISPOS, V25, P321
[5]
Boberg M, 1998, DRUG METAB DISPOS, V26, P640
[6]
NEW HYDROGEN-BOND POTENTIALS FOR USE IN DETERMINING ENERGETICALLY FAVORABLE BINDING-SITES ON MOLECULES OF KNOWN STRUCTURE [J].
BOOBBYER, DNA ;
GOODFORD, PJ ;
MCWHINNIE, PM ;
WADE, RC .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (05) :1083-1094
[7]
Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine [J].
Caron, G ;
Ermondi, G ;
Damiano, A ;
Novaroli, L ;
Tsinman, O ;
Ruell, JA ;
Avdeef, A .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (23) :6107-6118
[8]
Simvastatin [J].
Cejka, J ;
Kratochvíl, B ;
Císarová, I ;
Jegorov, A .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 2003, 59 (08) :O428-O430
[9]
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? [J].
Christians, U ;
Jacobsen, W ;
Floren, LC .
PHARMACOLOGY & THERAPEUTICS, 1998, 80 (01) :1-34
[10]
MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist [J].
Cruciani, G ;
Carosati, E ;
De Boeck, B ;
Ethirajulu, K ;
Mackie, C ;
Howe, T ;
Vianello, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6970-6979